Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
480
Recruiting, any sponsor type, condition "acute myeloid leukemia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting480
- Completed1,617
480 trials
Showing 1 to 25, recently updated first.
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruiting
Haikou Affiliated Hospital of Central South University Xiangya School of MedicineAcademic, hospital or other
NCT07763054 · 30 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 31, 2026
Drug: Liposomal Amphotericin B · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome and 6 more
Sites: Hainan, China
National Cancer Institute (NCI)NIH
NCT07437950 · 126 participants (planned) · Start Sep 25, 2026 · Primary completion Sep 22, 2034
Drug: Decitabine and Cedazuridine; Venetoclax · For: Acute Myeloid Leukemia
Sites: Coeur d'Alene, Idaho; Post Falls, Idaho; Sandpoint, Idaho · 83 sites in all
Orca Biosystems, Inc.Industry
NCT07216443 · 130 participants (planned) · Start Dec 9, 2025 · Primary completion Nov 2028
Drug: Orca-T · For: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Mixed Phenotype Acute Leukemia
Sites: Duarte, California; Los Angeles, California; Denver, Colorado · 9 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT04195633 · 60 participants (planned) · Start Jan 25, 2021 · Primary completion Apr 15, 2027
Drug: Cyclophosphamide; Cyclosporine and 5 more · For: Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 16 more
Sites: Seattle, Washington
Immune System Key LtdIndustry
NCT04365179 · 18 participants (planned) · Start Jun 18, 2020 · Primary completion Dec 31, 2027
Drug: Nerofe · For: Advanced MDS; AML
Sites: Miami, Florida
AbbVieAbbVie (ABBV)
NCT07581002 · 660 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2032
Drug: Pivekimab Sunirine; Venetoclax and 2 more · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Atlanta, Georgia · 40 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06928662 · 36 participants (planned) · Start Sep 23, 2025 · Primary completion Mar 9, 2028
Drug: Decitabine; Cytarabine and 3 more · For: Acute Myeloid Leukemia; Acute Undifferentiated Leukemia; Mixed Phenotype Acute Leukemia and 11 more
Sites: Seattle, Washington
- Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaPivotal-lookingRecruiting
Quetzal TherapeuticsIndustry
NCT07504458 · 150 participants (planned) · Start Jun 8, 2026 · Primary completion Mar 2027
Drug: QTX-2101 + ATRA; IV arsenic trioxide (ATO) + ATRA · For: Acute Promyelocytic Leukemia (APL); Acute Promyelocytic Leukaemia; Acute Promyelocytic Leukemia With PML-RARA and 2 more
Sites: Birmingham, Alabama; Duarte, California; Irvine, California · 39 sites in all
- Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLPivotal-lookingRecruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT06652438 · 448 participants (planned) · Start May 5, 2025 · Primary completion Dec 13, 2029
Drug: Revumenib; Placebo · For: Acute Myeloid Leukemia, Adult
Sites: Los Angeles, California; San Francisco, California; Atlanta, Georgia · 199 sites in all
PETHEMA FoundationAcademic, hospital or other
NCT07507760 · 50 participants (planned) · Start Jun 12, 2026 · Primary completion Apr 2029
Drug: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET; Ivosidenib Oral Tablet and 2 more · For: Acute Myeloid Leukemia With Gene Mutations
Sites: Aveiro, Portugal; Funchal, Portugal; Lisbon, Portugal · 21 sites in all
- A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Pivotal-lookingRecruiting
Debiopharm International SAIndustry
NCT06969430 · 154 participants (planned) · Start May 30, 2025 · Primary completion Nov 2031
Drug: Debio 1562M · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Chicago, Illinois · 7 sites in all
National Cancer Institute (NCI)NIH
NCT06672146 · 93 participants (planned) · Start May 16, 2025 · Primary completion Mar 31, 2027
Drug: Decitabine and Cedazuridine; Enasidenib and 1 more · For: Acute Myeloid Leukemia
Sites: Tucson, Arizona; Little Rock, Arkansas; Berkeley, California · 138 sites in all
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)Pivotal-lookingRecruiting
PETHEMA FoundationAcademic, hospital or other
NCT07478991 · 376 participants (planned) · Start Jul 2, 2026 · Primary completion Apr 2030
Drug: Azacitidine; Venetoclax and 1 more · For: Acute Myeloid Leukemia, Adult
Sites: Santiago de Compostela, Spain; Hospitalet Del Llobregat, Spain; Terrassa, Spain · 52 sites in all
Baylor College of MedicineAcademic, hospital or other
NCT06345027 · 78 participants (planned) · Start Apr 15, 2026 · Primary completion Jun 2029
Drug: Treatment Arm A · For: Leukemia, Myeloid, Acute; Leukemia, B-cell; Leukemia, T-Cell
Sites: Houston, Texas · 2 sites in all
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07925190 · 318 participants (planned) · Start Nov 3, 2026 · Primary completion Dec 2029
Drug: Mesutoclax (ICP-248); Azacitidine (AZA) and 1 more · For: Acute Myeloblastic Leukemia
Sites: Hangzhou, China
Incyte Biosciences International SàrlIncyte (INCY)
NCT03934372 · 70 participants (planned) · Start Jan 29, 2020 · Primary completion Feb 1, 2028
Drug: Ponatinib · For: Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia and 6 more
Sites: Ghent, Belgium; Paris, France; Poitiers, France · 23 sites in all
University of California, DavisAcademic, hospital or other
NCT07304011 · 28 participants (planned) · Start Dec 17, 2025 · Primary completion Dec 1, 2027
Drug: Azacitidine; Olutasidenib · For: Acute Myeloid Leukemia
Sites: Los Angeles, California; Orange, California; Sacramento, California
Marker Therapeutics, Inc.Industry
NCT06552416 · 40 participants (planned) · Start Jun 16, 2025 · Primary completion Sep 2029
Drug: MT-401-OTS · For: Acute Myeloid Leukemia, in Relapse; MDS
Sites: Duarte, California; Tampa, Florida; Kansas City, Kansas
University of Wisconsin, MadisonAcademic, hospital or other
NCT07758218 · 22 participants (planned) · Start Nov 2026 · Primary completion Oct 2029
Drug: agenT-797 · For: Allogenic Stem Cell Transplantation; Myeloid Malignancies; Lymphoid Malignancies and 3 more
Sites: Madison, Wisconsin
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPivotal-lookingRecruiting
Kura Oncology, Inc.Industry
NCT07007312 · 1,300 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 2031
Drug: Ziftomenib; Placebo and 4 more · For: Acute Myeloid Leukemia (AML)
Sites: Gilbert, Arizona; Clovis, California; La Jolla, California · 141 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07549464 · 12 participants (planned) · Start Aug 20, 2026 · Primary completion Jun 1, 2029
Drug: PLM-102 · For: Acute Myeloid Leukemia
Sites: Houston, Texas
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)Pivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06317649 · 147 participants (planned) · Start Sep 27, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Gilteritinib and 1 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 229 sites in all
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2Pivotal-lookingRecruiting
University of UlmAcademic, hospital or other
NCT04628026 · 650 participants (planned) · Start Sep 13, 2022 · Primary completion Mar 2029
Drug: Venetoclax; Placebo · For: Acute Myeloid Leukemia
Sites: Innsbruck, Austria; Linz, Austria; Rankweil, Austria · 91 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04774393 · 84 participants (planned) · Start May 24, 2021 · Primary completion Nov 29, 2027
Drug: Decitabine and Cedazuridine; Enasidenib and 2 more · For: Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Sites: Houston, Texas
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02115295 · 508 participants (planned) · Start May 19, 2014 · Primary completion May 31, 2030
Drug: Cladribine; Cytarabine and 4 more · For: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 11 more
Sites: Houston, Texas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.